Gilead Sciences
Gilead Sciences, Inc. (Nasdaq: GILD) is a biopharmaceutical company that discovers, develops and delivers medicines for life-threatening diseases, with a focus on HIV, viral hepatitis, COVID-19 and cancer. Its products include HIV treatment and prevention therapies such as Biktarvy, Descovy, Sunlenca and Yeztugo;… From the company’s description.
In fiscal 2025, Gilead Sciences reported revenue of $29.44B, up 2.4% from fiscal 2024, and net income of $8.51B. Its operating margin was 34.0%, and operations generated $10.02B in cash. Over the twelve months to Jun 30, 2026, revenue was $30.46B.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What Gilead Sciences does
In the company’s own words
Gilead Sciences, Inc. (Nasdaq: GILD) is a biopharmaceutical company that discovers, develops and delivers medicines for life-threatening diseases, with a focus on HIV, viral hepatitis, COVID-19 and cancer. Its products include HIV treatment and prevention therapies such as Biktarvy, Descovy, Sunlenca and Yeztugo; liver disease medicines including Epclusa, Vemlidy and Livdelzi; oncology therapies such as Yescarta, Tecartus and Trodelvy; and Veklury for COVID-19. Customers and users include patients and healthcare providers, with products distributed through commercial teams, wholesalers, distributors and corporate partners. Gilead also earns royalties and other revenue from licensing and collaboration arrangements. It operates in more than 35 countries and had approximately 17,000 employees as of December 31, 2025. The company’s research and development focuses primarily on virology, oncology and inflammation, and its portfolio includes products developed with partners. Its website is https://www.gilead.com.
Company details
- Sector
- Health Care
- Industry (SIC)
- Biological Products
- Headquarters
- FOSTER CITY, CA
- Fiscal year end
- December
- CIK
- 882095
- SIC
- 2836
Financial performance, year by year
Fiscal 2013–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns Gilead Sciences — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Largest fund holders · Gilead Sciences’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Gilead Sciences’s bonds, as funds hold them
Funds report holding 22 issues of Gilead Sciences’s debt, $2.42B at market value — what funds hold, not the company’s total debt. Weighted-average coupon 4.41%, maturing 2027 to 2064.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do Gilead Sciences and its peers compare on margins and cash generation over ten years?”
- “Where did five years of Gilead Sciences's earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in Gilead Sciences's last four quarterly filings that the numbers alone won't show?”